FluBlok, a recombinant hemagglutinin influenza vaccine
- PMID: 19453397
- PMCID: PMC4634115
- DOI: 10.1111/j.1750-2659.2008.00053.x
FluBlok, a recombinant hemagglutinin influenza vaccine
Abstract
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.
Similar articles
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. Vaccine. 2009. PMID: 19716456 Clinical Trial.
-
FluBlok, a next generation influenza vaccine manufactured in insect cells.Biologicals. 2009 Jun;37(3):182-9. doi: 10.1016/j.biologicals.2009.02.014. Epub 2009 Mar 17. Biologicals. 2009. PMID: 19297194 Review.
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28. Vaccine. 2011. PMID: 21277410 Clinical Trial.
-
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9. Vaccine. 2011. PMID: 21835220 Clinical Trial.
-
Production of a novel influenza vaccine using insect cells: protection against drifted strains.Influenza Other Respir Viruses. 2007 Jan;1(1):35-40. doi: 10.1111/j.1750-2659.2006.00007.x. Influenza Other Respir Viruses. 2007. PMID: 19453478 Free PMC article. Review.
Cited by
-
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses.Cell Rep Med. 2021 Apr 20;2(4):100252. doi: 10.1016/j.xcrm.2021.100252. Epub 2021 Apr 5. Cell Rep Med. 2021. PMID: 33842900 Free PMC article.
-
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.Hum Vaccin Immunother. 2015;11(5):1277-92. doi: 10.1080/21645515.2015.1016675. Hum Vaccin Immunother. 2015. PMID: 25751641 Free PMC article. Review.
-
An Overview of Influenza Viruses and Vaccines.Vaccines (Basel). 2021 Sep 17;9(9):1032. doi: 10.3390/vaccines9091032. Vaccines (Basel). 2021. PMID: 34579269 Free PMC article. Review.
-
Multi-strain modeling of influenza vaccine effectiveness in older adults and its dependence on antigenic distance.Sci Rep. 2024 Nov 8;14(1):27190. doi: 10.1038/s41598-024-72716-1. Sci Rep. 2024. PMID: 39516205 Free PMC article.
-
Targeting neuraminidase: the next frontier for broadly protective influenza vaccines.Trends Immunol. 2024 Jan;45(1):11-19. doi: 10.1016/j.it.2023.11.001. Epub 2023 Dec 15. Trends Immunol. 2024. PMID: 38103991 Free PMC article. Review.
References
-
- Wood JM. Standardization of Inactivated Influenza Vaccine; in Nicholson KG, Webster RG Hay AJ (eds): Textbook of Influenza London: Blackwell Science, Ltd, 1998; 333–345.
-
- Centers for Disease Control (CDC) . ACIP. Prevention and control of influenza, recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report (MMWR) 2002; 51:1–31. - PubMed
-
- Huber VC, JA Cullers. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 2008; 10:75–85. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials